ChroMedX Corp. Information to be Available through S&P Capital IQ Corporation Records Program

Toronto, Ontario
September 26, 2014

ChroMedX Corp. (OTC: MNLIF) (CSE: CHX) announced today that its company information would be made available via S&P Capital IQ Corporation Records Listing Program. As part of the program, a full description of ChroMedX Corp. will be published in the Daily News Section of Standard & Poors's Corporation Records, a recognized securities manual for secondary trading in up to 38 States under the Blue Sky Laws. S&P Capital IQ Corporation Records is available in print, CD-ROM, and via the web at www.netadvantage.standardandpoors.com as well as through numerous electronic vendors.

The company information about ChroMedX Corp. to be made available through this program includes an in-depth description of ChroMedX's business operations, share price, dividend history, shares outstanding, company financial position, earnings, and full income statement and balance sheet.

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. ChroMedX Technologies are protected by the Company's issued US and pending international patents, dealing with blood collection, analysis and plasma/serum processing.

The Company previously operated as Monarch Energy Ltd. before the formal name change on September 18, 2014 to ChroMedX Corp. The Company commenced trading on the OTC and CSE in Canada on July 7, 2014.

About S&P Capital IQ

S&P Capital IQ, a part of McGraw Hill Financial, is a leading provider of multi-asset class and real time data, research and analytics to institutional investors, investment and commercial banks, investment advisors and wealth managers, corporations and universities around the world. Evaluated pricing is prepared by Standard & Poor's Securities Evaluations, Inc., a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. In the United States, research reports are prepared by Standard & Poor's Investment Advisory Services LLC, a part of S&P Capital IQ and a registered investment adviser with the U.S. Securities and Exchange Commission. S&P Capital IQ provides a broad suite of capabilities designed to help track performance, generate alpha, and identify new trading and investment ideas, and perform risk analysis and mitigation strategies. Through leading desktop solutions such as the S&P Capital IQ, Global Credit Portal and MarketScope Advisor desktops; enterprise solutions such as S&P Capital IQ Valuations; and research offerings, including Leveraged Commentary & Data, Global Markets Intelligence, and company and funds research, S&P Capital IQ sharpens financial intelligence into the wisdom today's investors need. For more information visit: www.spcapitaliq.com

Company information distributed through the Corporation Records Program is based upon information that S&P Capital IQ considers to be reliable, but neither S&P Capital IQ nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument.

Contacts:
ChroMedX Corp. 
W. Clark Kent 
647-519-2646 
ckent@chromedx.com

Website: 
www.chromedx.com

S&P Capital IQ 
Equity Research Operations, 212-438-4050 
ers_businessoperations@spcapitaliq.com

S&P Capital IQ Media Relations Contact: 
Michael Privitera, 212 438-6679 
michael.privitera@spcapitaliq.com